By bringing together exceptional researchers, innovators, and entrepreneurs, STRM.BIO is opening the door to the future of medicine for patients worldwide with a better way to deliver gene therapies. Our team has founded biotech companies, developed effective therapies, and successfully brought new products to market. We have the drive, vision, and the experience to fulfill the promise of gene therapy
Kellie is a principal investigator in the Vascular Biology Program at Boston Children’s Hospital. She is an expert in megakaryocyte- and platelet-derived extracellular vesicles and their role in megakaryocyte differentiation and inflammation.
George is a Senior Fellow and Honorary Consultant Hematologist at Cambridge University Hospitals and heads the Haematological Cancer Genetics Group at the Sanger Institute. His research focuses on clonal hematopoiesis and the pathogenesis of blood cancers.
Lindsey is an attending Physician in the Division of Hematology at Children’s Hospital of Philadelphia. She has led early phase clinical trials in AAV-mediated gene transfer for hemophilia with a focus on hemostasis and thrombosis disorders.
Eric is the FDA Alternate Industry Representative on the Cellular, Tissue and Gene Therapies Advisory Committee since Jan 2020. Prior to Ultragenyx, he served as CMO at Dimension Therapeutics.
Jon manages process and product development programs at Rooster Bio (previously their CEO and Technology Officer). Before Rooster, he served as innovation director, cell processing technologies at Lonza. Jon specializes in technology road-mapping, cell therapy biomanufacturing, biomaterials, and tissue engineering.